Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 41S Rio Grande Street SALT LAKE CITY UT 84101 |
Tel: | N/A |
Website: | https://www.recursion.com |
IR: | See website |
Key People | ||
Tina Marriott Larson President, Chief Operating Officer | Christopher Gibson Chief Executive Officer, Director | Michael Secora Chief Financial Officer | David J. Mauro Chief Medical Officer |
Business Overview |
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection. |
Financial Overview |
For the fiscal year ended 31 December 2023, Recursion Pharmaceuticals Inc revenues increased 12% to $44.6M. Net loss increased 37% to $328.1M. Revenues reflect Grant revenue increase from $162K to $699K. Higher net loss reflects Research & Development Expense - Balanci increase of 42% to $186.4M (expense), Stock-based Compensation in R&D increase from $10.1M to $22M (expense), Stock-Based Compensation increase of 73% to $24.4M (expense). |
Employees: | 500 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,709M as of Dec 31, 2023 |
Annual revenue (TTM): | $44.58M as of Dec 31, 2023 |
EBITDA (TTM): | -$324.31M as of Dec 31, 2023 |
Net annual income (TTM): | -$328.07M as of Dec 31, 2023 |
Free cash flow (TTM): | -$299.74M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 237,617,203 as of Apr 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |